Christian Bach

University Hospital Leipzig

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Andréas Mackensen

Friedrich-Alexander-Universität Erlangen-Nürnberg

Heiko Bruns

Universitätsklinikum Erlangen

Bernd M. Spriewald

Universitätsklinikum Erlangen

Robert K. Slany

Friedrich-Alexander-Universität Erlangen-Nürnberg

Dimitrios Mougiakakos

Otto-von-Guericke University Magdeburg

Maike Büttner‐Herold

Universitätsklinikum Erlangen

Fabian Beier

RWTH Aachen University

Katrin Bitterer

Universitätsklinikum Erlangen

Hassan Bajwa

Government College University, Faisalabad

Heidi Balzer

Friedrich-Alexander-Universität Erlangen-Nürnberg

Cooperative Institutions

Friedrich-Alexander-Universität Erlangen-Nürnberg

Universitätsklinikum Erlangen

Harvard University

University Hospital Regensburg

Heidelberg University

University of Regensburg

RWTH Aachen University

University of Bridgeport

Ludwig-Maximilians-Universität München

Inserm

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Hematopoietic Differentiation Is Required for Initiation of Acute Myeloid Leukemia

Cell stem cell (2015)

Min Ye Hong Zhang Henry Yang Richard P. Koche Philipp B. Staber

10.1016/j.stem.2015.08.011

Cite

Citations (109)

Ovarian Cancer risk factors and Their Mechanism of Action

European Journal of Engineering and Technology Research (2018)

Modinat Jolade Adaranijo Christian Bach

Ovarian cancer continues to be one of the deadliest and lethal form of gynecological cancer affecting younger and older woman. Understanding various factors that could lead to ovarian cancer and how they are able to drive its progression, metastasis and survival might help in its treatment and prevention. This paper aims to review different risk factors both genetic and environmental that could lead to the development of ovarian cancer and their mechanism of action. The research methods used in this study follows the principles outlined by [1]. It is a comprehensive literature review on ovarian cancer risk factor. The role of genetics and environmental risk factors in ovarian carcinogenesis and their mechanism of action created a theoretical foundation of the paper. A new model is presented to encapsulate highly dynamic interaction between ovarian carcinogenesis and the mechanism of action of some associated risk factors. The contribution of the study is intended to review and summarize the theoretical and empirical knowledge that should inspire new discussions and directions for further research activity. The model highlights various factors that can trigger the development of ovarian cancer namely; TP53, BRCA genes, Cigarette smoke and Talc powder and how they are able to promote ovarian cancer. Various have been done about how mutation of certain genes and some environmental factors could lead to ovarian carcinogenesis. However, more research is needed to further understand how their mechanism of action. The content of this paper will be useful in devising a better screening, treatment and preventive measure towards the ovarian cancer. This study provides an exciting opportunity to advance our knowledge of ovarian cancer to efficiently aid medical practitioners and researchers to device better prevention and treatment plan to combat ovarian cancer.

Preventive action

10.24018/ejers.2018.3.2.617

Cite

Citations (0)

NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML

Blood (2014)

Sophia Adamia Michal Bar‐Natan Benjamin Haibe‐Kains Patrick M. Pilarski Christian Bach

splice

10.1182/blood-2013-02-481507

Cite

Citations (46)

Heat targeted drug delivery (COMBAT) in superficial TCC : First midterm results in a cohort of high-risk patients scheduled for cystectomy.

Journal of Clinical Oncology (2018)

Thomas Alexander Voegeli Eric Frank Christian Bach Catejan Nzeh

442 Background: Due to the suboptimal outcomes in recurrent superficial TCC over the last 30 years the search for new treatments continues. We report the first mid term results of a high risk cohort of heavily pretreated patients by a circulating device for intravesical thermochemotherapy.It is known that the effect of mitomycin increases at a temperature over 40 C. Methods: 58 patients with different failed methods of former intravesical therapy and recurrent TCC (21 intermediate risk and 37 high risk patients) were treated with the COMBAT device which facilitates irrigation of the bladder with mitomycin 40 mg at exactly 43 degree Celsius for 1 hour/6 courses weekly.Side effects were monitored prospectively and success of the treatment was controlled by ReTUR whenever possible and afterwards by 3 monthly cystoscopy and cytology. Results: 22 patients had dysuria during treatment and 9/58 suffered from hematuria but without intervention. In 6 cases urinary tract infection occured and 3 patients had allergic reaction. In one patient thermochemotherapy must be terminated due to pain and discomfort, no long term morbidity was recorded over the whole period. The FU was 14 month (3-29) for the entire cohort, 17 patients had a FU of over 2 years. One Patient had recurrent pTaGIII Tumor managed successfully by TUR. 2 patients underwent cystectomy because of invasive recurrence early after intravesical therapy, one patient developed bone metastasis 2 years after therapy without intravesical tumor. Conclusions: Thermochemotherapy with heated mitomycin is a well tolerated new option for patients with superficial TCC who are at high risk of recurrence or progression.The toxicity is acceptable and no long term morbidity was obeserved. The rate of cystectomies in this heavily pretreated group of patients including 18 BCG failures was very low with N= 2 respective 1,9%. Intravesical thermochemotherapy seems to be a new therapeutic bladder preserving option in high risk patients with superficial TCC. It is of note that thermochemotherapy has now been included in the European Guidelines.

Dysuria

Mitomycin C

10.1200/jco.2018.36.6_suppl.442

Cite

Citations (0)

[Table of Contents]

IEEE/ACM Transactions on Computational Biology and Bioinformatics (2013)

Seth Blumenthal Yisheng Tang Wenjie Yang Brian Chen Said Bleik

about the cover image: Finding amino acids in the minor groove.(a) Atoms from DNA chains in 1 HLZ, from the PDB (spheres).(b) Molecular surface of DNA (transparent yellow), phosphates in DNA backbone (magenta).(c) Catmull-Rom spline (gray).(d) Diagram of triangle ribbon assembly, corner points (green circles), triangle edges (black lines).(e) Finished ribbon (transparent yellow).(f) Finished ribbon (teal).On the molecular surface of DNA (black outline), blue regions are distant, white regions intermediate, red regions are nearby the ribbon.(g) Atomic structure of DNA, rotated (spheres).Ribbon (transparent yellow), arginine intersecting the ribbon and the minor groove (yellow, black outline).

Table (database)

10.1109/tcbb.2013.180

Cite

Citations (0)

Transition metals modulate DNA-protein interactions of SP1 zinc finger domains with its cognate target site

Biochemical and Biophysical Research Communications (1991)

Hans‐Jürgen Thiesen Christian Bach

Divalent

Sp1 transcription factor

Metalloprotein

Protein–DNA interaction

10.1016/s0006-291x(05)80219-0

Cite

Citations (78)

Mechanistic Characterization of Tafasitamab-Mediated Antibody-Dependent Cellular Phagocytosis Alone or in Combination with Lenalidomide

Blood (2019)

Dimitrios Mougiakakos Simon Voelkl Christian Bach Andrej Stoll Katrin Bitterer

10.1182/blood-2019-124886

Cite

Citations (9)

Monitoring of Hematopoietic Chimerism by Real-Time Quantitative PCR of Micro Insertions/Deletions in Samples with Low DNA Quantities

Transfusion Medicine and Hemotherapy (2015)

Christian Bach Elmira Tomova Katja Goldmann Volker Weisbach Wolf Roesler

Background: Sensitive and accurate methods to detect hematopoietic chimerism after hematopoietic stem cell transplantation (HSCT) are essential to evaluate engraftment and to monitor response to therapeutic procedures such as donor lymphocyte infusion. Continuous long-term follow up, however, requires large amounts of pre-HSCT samples limiting the application of many widely used techniques for sensitive chimerism monitoring. Methods: DNAs from 42 normal healthy donors and 16 HSCT donor/recipient pairs were employed to validate the use of allele-specific insertion/deletion (indel) quantitative real-time polymerase chain reaction (qPCR) to quantify chimerism in samples with low amounts of DNA. Consequently, indel-qPCR analyses of samples from 16 HSCT patients were compared to short-tandem repeat (STR) specific PCR analyses. Results: Typing with reduced amounts of input DNA (15 vs. 60 ng) allowed for the reliable distinction of positive (mean threshold cycle (ct) 28.05) and negative (ct >36) signals. The high informativity of primer/probe sets, with 12 out of 19 markers exceeding 20% informativity, was confirmed in our cohort (n = 74). Importantly, a fourfold reduction of input DNA compared to published protocols did not alter PCR efficiencies and allowed for a more sensitive detection of chimerism in 7 of 16 HSCT patients compared to results obtained by STR-PCR. Conclusions: Our data suggest that indel-qPCR is a more sensitive technique for the detection of hematopoietic chimerism compared to STR-PCR and works efficiently for samples with low amounts of DNA.

10.1159/000370255

Cite

Citations (27)

Worin besteht der Nutzen der Wirtschaftsprüfung

Reto Eberle Christian Jaag Christian Bach

Source

Cite

Citations (0)

Analysis of Luminex-based Algorithms to Define Unacceptable HLA Antibodies in CDC-crossmatch Negative Kidney Transplant Recipients

Transplantation (2018)

Daniel Zecher Christian Bach Adrian Preiss Christoph Staudner Kirsten Utpatel

HLA-specific antibodies detected by solid phase assays are increasingly used to define unacceptable HLA antigen mismatches (UAM) before renal transplantation. The accuracy of this approach is unclear.Day of transplant sera from 211 complement-dependent cytotoxicity crossmatch-negative patients were retrospectively analyzed for donor-specific anti-HLA antibodies (DSA) using Luminex technology. HLA were defined as UAM if DSA had mean fluorescence intensity above (I) 3000 (patients retransplanted and those with DSA against HLA class I and II) or 5000 (all other patients), (II) 5000 for HLA-A, -B, and -DR and 10 000 for HLA DQ or (III) 10 000 (all HLA). We then studied the accuracy of these algorithms to identify patients with antibody-mediated rejection (AMR) and graft loss. UAM were also determined in 256 transplant candidates and vPRA levels calculated.At transplantation, 67 of 211 patients had DSA. Of these, 31 (algorithm I), 24 (II) and 17 (III) had UAM. Nine (I and II) and 8 (III) of 11 early AMR episodes and 7 (I), 6 (II) and 5 (III) of 9 graft losses occurred in UAM-positive patients during 4.9 years of follow-up. Algorithms I and II identified patients with persistently lower glomerular filtration rate even in the absence of overt AMR. Of the waiting list patients, 22-33% had UAM with median virtual panel reactive antibody of 69.2% to 79.1%.Algorithms I and II had comparable efficacy but were superior to Algorithm III in identifying at-risk patients at an acceptable false-positive rate. However, Luminex-defined UAM significantly restrict the donor pool of affected patients, which might prolong waiting time.

Donor-Specific Antibodies

10.1097/tp.0000000000002129

Cite

Citations (14)